Clinical improvement in psoriasis with treatment of associated hyperlipidemia

American Journal of the Medical Sciences

Volumn 341, Issue 5, 2011, Pages 394-398

  Ghazizadeh, Ramin ^a,b   Tosa, Mamiko ^b   Ghazizadeh, Mohammad ^b  

^a Academic Dermatology and Skin Cancer Institute   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Atherosclerosis; Clinical improvement; Hyperlipidemia; Psoriasis; Statins; Therapy

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; ARACHIDONIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CYCLOSPORIN; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; MEVINOLIN; OMEGA 3 FATTY ACID; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL INTAKE; CLINICAL ASSESSMENT; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; ENCEPHALITIS; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE ADHERENCE; LIPID METABOLISM; LIVER TOXICITY; LOW FAT DIET; MULTIPLE SCLEROSIS; NEPHROTOXICITY; PATHOGENESIS; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RECEPTOR DOWN REGULATION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; TREATMENT DURATION;

EID: 79955524223     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181ff8eeb     Document Type: Review

References (63)

1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64(suppl 2):ii18 -23. (Pubitemid 40288514)
2. Jobling R, Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol 2006;126:1438-40.
3. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007;25: 529-34. (Pubitemid 350087599)
4. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238-44. (Pubitemid 8387357)
5. Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 2004;151:381-7. (Pubitemid 39215151)
6. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? Facts and controversies. Clin Dermatol 2010;28:67-72.
7. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Bt J Dermatol 2008;159:895-902.
8. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41. (Pubitemid 44547793)
9. Choi WJ, Park EJ, Kwon IH, et al. Association between psoriasis and cardiovascular risk factors in Korean patients. Ann Dermatol 2010;22: 300-6.
10. Ghoreschi K, Mrowietz U, Roc̈ken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med 2003;81:471-80. (Pubitemid 37070199)
11. Makgoba MW, Sanders ME, Shaw S. The CD2-LFA-3 and LFA-1- ICAM pathways: relevance to T-cell recognition. Immunol Today 1989;10:417-22. (Pubitemid 19277301)
12. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130:1373-83.
13. Fujishima S, Watanabe H, Kawaguchi M, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res 2010;302:499-505.
14. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005;102:19057-62. (Pubitemid 43049565)
15. Michelle A Lowes, Anne M, et al. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.
16. Gottlieb AB, Chamain F, Masud S, et al. TNF inhibition rapidly down-regulates multiple pro-inflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-9. (Pubitemid 41113889)
17. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-33. (Pubitemid 27098094)
18. Wang J, Al-Lamki RS, Zhang H, et al. Histamine antagonizes tumor necrosis factor (TNF) signalling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem 2003;278: 21751-60. (Pubitemid 36792578)
19. Robak T, Gladalska A, Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998;9:145-54. (Pubitemid 28301573)
20. Nurnberger W, Platonov A, Stannigel H, et al. Definition of a new score for severity of generalized Neisseria meningitidis infection. Eur J Pediatr 1995;154:896-900.
21. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-57. (Pubitemid 17010024)
22. Kwiatkowski D, Hill AV, Sambou I, et al. TNF concentration in fatal cerebral, non-fatal cerebral and uncomplicated Plasmodium falciparum malaria. Lancet 1990;336:1201-4. (Pubitemid 20382913)
23. Bouwmeester T, Bauch A, Ruffner H, et al. A physical and functional map of the human TNFα/NF-κB signal transduction pathway. Nat Cell Biol 2004;6:97-105. (Pubitemid 38425708)
24. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74. (Pubitemid 41443403)
25. Menter A, Feldman SR, Weinstein GD, et al. A randomized com- parison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31.e1-15.
26. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008;159:322-30. (Pubitemid 352009830)
27. Coimbra S, Oliveria H, Reis F, et al. C-reactive protein and leukocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010;24:789-96.
28. Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl 2006;7:31-5.
29. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92. (Pubitemid 32588024)
30. Raemer PC, Kohl K, Watzl C. Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol 2009;39:1456-65.
31. Pozo M, de Nicolas R, Egido J, et al. Simvastatin inhibits the migration and adhesion of monocytic cells and disorganizes the cytoskeleton of activated endothelial cells. Eur J Pharmacol 2006;548:53-63. (Pubitemid 44397017)
32. McGown CC, Brookes ZL. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br J Anaesth 2007; 98:163-75. (Pubitemid 47071995)
33. Liu W, Li WM, Gao C, et al. Effect of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in lewis rats. J Autoimmun 2005;25:258-63. (Pubitemid 41642971)
34. Cheng X, Ding Y, Xia C, et al. Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail 2009;15: 158-62.
35. Menge T, Hartung HP, Stuve O. Statins - a cure-all for the brain? Nat Rev Neurosci 2005;6:325-31.
36. Araujo FA, Rocha MA, Mendes JB, et al. Atorvastatin inhibits inflammatory angiogenesis in mice through downregulation of VEGF, TNF-alpha and TGF-beta-1. Biomed Pharmacother 2010;64:29-34.
37. Loppnow H, Zhang L, Buerke M, et al. Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures [published online ahead of print February 16, 2010]. J Cell Mol Med. doi: 10.1111/j.1582-4934.2010.01036.x.
38. Xu Y, Tang T, Ding Y, et al. Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction. Am J Med Sci 2010;340:121-7.
39. Mandosi E, Fallarino M, Gatti A, et al. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. J Atheroscler Thromb 2010;17:539-45.
40. Vasiuk IuA, Perlamutrov IuN, Shkol'nik MN, et al. [Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension.] Kardiologiia 2010;50:37-46.
41. Kwak B, Multhaupt F, Myit S, et al. Statins as newly recognized type of immunomodulator. Nature 2000:1399-402. (Pubitemid 32001026)
42. Kuipers HF, van den Elsen PJ. Statins and control of MHC2TA gene transcription. Nat Med 2005;11:365-6.
43. Ehrenstein MR, Jury EC, Mauri C. Statins for atherosclerosis-as good as it gets? N Engl J Med 2005;352:73-5.
44. Stanislaus R, Pahan K, Singh AK, et al. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 1999;269:71-4. (Pubitemid 29335415)
45. Youssef F, Stüve O, Patarraoyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84. (Pubitemid 35291443)
46. Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003;197:725-33. (Pubitemid 36350867)
47. Sena A, Pedrosa R, Graca MM. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 2003;250:754-5. (Pubitemid 36718367)
48. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-8. (Pubitemid 38625664)
49. McCarey DW, McInnes IB, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004;363:2015-21. (Pubitemid 38781100)
50. Kragballe K, Fogh K. A low-fat diet supplemented with dietary fish oil (Max-EPA) results in improvement of psoriasis and in formation of leukotriene B 5. Acta Derm Venereol 1989;69:23-8. (Pubitemid 19028327)
51. Rucevic I, Perl A, Barisic-Drusko V, et al. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol 2003;27(suppl 1): 41-8. (Pubitemid 38340151)
52. Lithell H, Bruce A, Gustafsson IB, et al. A fasting and vegetarian diet treatment trial on chronic inflammatory disorders. Acta Derm Venereol (Stockh) 1983;63:397-403.
53. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6.
54. Naldi L, Parazzini F, Peli L, et al. Dietary factors and the risk of psoriasis. Results of an Italian case- control study. Br J Dermatol 1996;134:101-6. (Pubitemid 26029668)
55. Grimble RF, Tappia PS. Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids. Z Ernahrungswiss 1998; 37(suppl 1):57-65. (Pubitemid 28161261)
56. Hercogová J, Ricceri F, Tripo L, et al. Psoriasis and body mass index. Dermatol Ther 2010;23:152-4.
57. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index and stressful life events as risk factors for psoriasis: result from an Italian case-control study. J Invest Dermatol 2005;125:61-7. (Pubitemid 40981424)
58. Setty AR, Curhan G, Chointerni HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women. Arch Intern Med 2007;167:1670-5. (Pubitemid 47280349)
59. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol 2007;57:529-31. (Pubitemid 47239149)
60. Wolkenstein P, Revuz J, Roujeau JC, et al. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology 2009;218:103-9.
61. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349: 2004-13. (Pubitemid 37448923)
62. Namazi MR. Statins: novel additions to the dermatologic arsenal? Exp Dermatol 2004;13:337-9. (Pubitemid 38868205)
63. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70. (Pubitemid 32606333)